Anika Therapeutics, Inc. Form DEFA14A April 24, 2015

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

SCHEDULE 14A

Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.

	the Sec	curries Exchange Act of 1934 (Amendment No.
Filed by a P	Registrant [X] arty other than the Regippropriate box:	istrant []
[] [] [X] []		Preliminary Proxy Statement Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) Definitive Proxy Statement Definitive Additional Materials Soliciting Material Pursuant to §240.14a-12
		ANIKA THERAPEUTICS, INC. of Registrant as Specified In Its Charter)
	(Name of Person(s)	Filing Proxy Statement, if other than the Registrant)
Payment of [X]	Filing Fee (Check the a No fee required Fee computed (1)	
	(2)	Aggregate number of securities to which transaction applies:
	(3)	Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):
	(4)	Proposed maximum aggregate value of transaction:
	(5)	Total fee paid:
[]	Check box if a identify the fili	ously with preliminary materials. ny part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and for which the offsetting fee was paid previously. Identify the previous filing by tement number, or the Form or Schedule and the date of its filing. Amount Previously Paid:
	(2)	Form, Schedule or Registration Statement No.:
	(3)	Filing Party:

Edgar Filing: Anika Therapeutics, Inc. - Form DEFA14A

Date Filed:

(4)